Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibecotamab (MRG003) in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Urinary Tract
ChiCTR2600126786Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in Mixed urothelial carcinoma with squamous differentiation (UCSD), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Mixed urothelial carcinoma with squamous differentiation (UCSD)
Beyond the preview
Go deeper on ChiCTR2600126786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126786.